Latanoprost sustained release implant (Pfizer/EyePoint)

N/A

Report date: 2022/02/18 15:31:58

Base Information

Drug NameLatanoprost sustained release implant (Pfizer/EyePoint)
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionProstaglandin agonists
TargetsProstaglandin
Therapy Area/IndicationsGlaucoma, Open-AngleOcular Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer IncPsivida
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPsividaPfizer Inc
Active IndicationsN/A
Inactive IndicationsGlaucoma, Open-AngleOcular Hypertension

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG